Hyo-Soo Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7586837/publications.pdf

Version: 2024-02-01

168 papers	10,714 citations	61687 45 h-index	37326 100 g-index
172 all docs	172 docs citations	172 times ranked	11407 citing authors

#	Article	IF	Citations
1	De-escalation of Prasugrel Results in Higher Percentage of Patients within Optimal Range of Platelet Reactivity: Analysis from the HOST-REDUCE-POLYTECH-ACS Trial. Thrombosis and Haemostasis, 2022, 122, 160-162.	1.8	4
2	Correction to: â€œCardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysisâ€• Journal of Lipid and Atherosclerosis, 2022, 11, 89.	1.1	2
3	The current status and outcomes of in-hospital P2Y12 receptor inhibitor switching in Korean patients with acute myocardial infarction. Korean Journal of Internal Medicine, 2022, , .	0.7	1
4	Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI. Korean Circulation Journal, 2022, 52, 304.	0.7	7
5	Enhanced Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood and Using Their Mesoderm Differentiation Ability to Regenerate Infarcted Myocardium. Stem Cells International, 2022, 2022, 1-19.	1.2	0
6	Cardiovascular Regeneration via Stem Cells and Direct Reprogramming: A Review. Korean Circulation Journal, 2022, 52, 341-353.	0.7	4
7	Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. JAMA Cardiology, 2022, 7, 418.	3.0	9
8	Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study. Clinical Hypertension, 2022, 28, 7.	0.7	0
9	The G Protein-Coupled Receptor Latrophilin-2, A Marker for Heart Development, Induces Myocardial Repair After Infarction. Stem Cells Translational Medicine, 2022, 11, 332-342.	1.6	2
10	Optimal low-density lipoprotein cholesterol target level in Korean acute myocardial infarction patients (<70Âmg/dL vs. <55Âmg/dL): Based on Korea acute myocardial infarction registry-National Institute of Health. International Journal of Cardiology, 2022, 351, 15-22.	0.8	3
11	The Clinical Impact of Î²-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention. Korean Circulation Journal, 2022, 52, 544.	0.7	2
12	Platelet Function and Genotype after DES Implantation in East Asian Patients: Rationale and Characteristics of the PTRG-DES Consortium. Yonsei Medical Journal, 2022, 63, 413.	0.9	13
13	Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 475-482.	1.4	27
14	Benefit of a staged inâ€hospital revascularization strategy in hemodynamically stable patients with STâ€segment elevation myocardial infarction and multivessel disease: Analyses by risk stratification. Catheterization and Cardiovascular Interventions, 2021, 97, 1151-1159.	0.7	3
15	Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 112-124.	1.4	13
16	Lysophosphatidic Acid Receptor 4 Is Transiently Expressed during Cardiac Differentiation and Critical for Repair of the Damaged Heart. Molecular Therapy, 2021, 29, 1151-1163.	3.7	11
17	Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. Circulation, 2021, 143, 1081-1091.	1.6	33
18	Association Between Low Muscle Mass and Prognosis of Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2021, 10, e018554.	1.6	8

#	Article	IF	Citations
19	Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis. Journal of Lipid and Atherosclerosis, 2021, 10, 210.	1.1	3
20	2021 Korean Society of Myocardial Infarction Expert Consensus Document on Revascularization for Acute Myocardial Infarction. Korean Circulation Journal, 2021, 51, 289.	0.7	11
21	Procedural optimization of <scp>drugâ€coated</scp> balloons in the treatment of coronary artery disease. Catheterization and Cardiovascular Interventions, 2021, 98, E43-E52.	0.7	8
22	Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk. Journal of Korean Medical Science, 2021, 36, e268.	1.1	1
23	Relative Impact of Clinical Risk Versus Procedural Risk on Clinical Outcomes After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2021, 14, e009642.	1.4	13
24	Clinical outcomes of long stenting in the drug-eluting stent era: patient-level pooled analysis from the GRAND-DES registry. EuroIntervention, 2021, 16, 1318-1325.	1.4	19
25	Long-term efficacy of vasodilating Î²-blocker in patients with acute myocardial infarction: nationwide multicenter prospective registry. Korean Journal of Internal Medicine, 2021, 36, S62-S71.	0.7	3
26	Left Ventricular Ejection Fraction 1 Year After Acute Myocardial Infarction Identifies the Benefits of the Long-Term Use of Î²-Blockers. Circulation: Cardiovascular Interventions, 2021, 14, e010159.	1.4	10
27	The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2021, 98, E332-E341.	0.7	1
28	Adhesion GPCR Latrophilin-2 Specifies Cardiac Lineage Commitment through CDK5, Src, and P38MAPK. Stem Cell Reports, 2021, 16, 868-882.	2.3	10
29	HLA DR Genome Editing with TALENs in Human iPSCs Produced Immune-Tolerant Dendritic Cells. Stem Cells International, 2021, 2021, 1-14.	1.2	9
30	Immediate Compared With Delayed Percutaneous Coronary Intervention for Patients With ST-Segmentâ€“Elevation Myocardial Infarction Presenting â‰¥12 Hours After Symptom Onset Is Not Associated With Improved Clinical Outcome. Circulation: Cardiovascular Interventions, 2021, 14, e009863.	1.4	5
31	Plant callus-derived shikimic acid regenerates human skin through converting human dermal fibroblasts into multipotent skin-derived precursor cells. Stem Cell Research and Therapy, 2021, 12, 346.	2.4	6
32	Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet, The, 2021, 397, 2487-2496.	6.3	162
33	Discovery of chemerin as the new chemoattractant of human mesenchymal stem cells. Cell and Bioscience, 2021, 11, 120.	2.1	4
34	KAI1(CD82) is a key molecule to control angiogenesis and switch angiogenic milieu to quiescent state. Journal of Hematology and Oncology, 2021, 14, 148.	6.9	18
35	Tenâ€Year Trends in Coronary Bifurcation Percutaneous Coronary Intervention: Prognostic Effects of Patient and Lesion Characteristics, Devices, and Techniques. Journal of the American Heart Association, 2021, 10, e021632.	1.6	10
36	Retinol from hepatic stellate cells via STRA6 induces lipogenesis on hepatocytes during fibrosis. Cell and Bioscience, 2021, 11, 3.	2.1	18

#	Article	IF	Citations
37	A First-in-Man Clinical Evaluation of Sirolimus and Ascorbic Acid-Eluting Stent Systems: a Multicenter, Subject-Blinded, Randomized Study. Korean Circulation Journal, 2021, 51, 1001.	0.7	4
38	Multivessel versus IRA-only PCI in patients with NSTEMI and severe left ventricular systolic dysfunction. PLoS ONE, 2021, 16, e0258525.	1.1	0
39	Percutaneous Treatment of Unprotected Left Main Disease With Thin-Strut Durable-Polymer or Early Generation Thicker-Strutted and Coated Bioabsorbable-Polymer Drug-Eluting Stents in a Large-Scale Registry. Cardiovascular Revascularization Medicine, 2021, 32, 43-49.	0.3	0
40	Intravascular modalityâ€guided versus angiographyâ€guided percutaneous coronary intervention in acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2020, 95, 696-703.	0.7	25
41	Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. European Heart Journal, 2020, 41, 239-252.	1.0	61
42	NFATc1+CD31+CD45â^' circulating multipotent stem cells derived from human endocardium and their therapeutic potential. Biomaterials, 2020, 232, 119674.	5.7	4
43	Clinical Implications of Bifurcation Angles in Left Main Bifurcation Intervention Using a Two-Stent Technique. Journal of Interventional Cardiology, 2020, 2020, 1-12.	0.5	3
44	Optimal Revascularization Strategy in Nonâ€“STâ€Segmentâ€“Elevation Myocardial Infarction With Multivessel Coronary Artery Disease: Culpritâ€Only Versus Oneâ€Stage Versus Multistage Revascularization. Journal of the American Heart Association, 2020, 9, e016575.	1.6	23
45	Optimal Dose and Type of Î²-blockers in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2020, 137, 12-19.	0.7	3
46	Hepatic stellate cellâ€“specific knockout of transcriptional intermediary factor 1Î³ aggravates liver fibrosis. Journal of Experimental Medicine, 2020, 217, .	4.2	16
47	Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet, The, 2020, 396, 1079-1089.	6.3	125
48	Efficacy and safety of coâ€administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. Journal of Clinical Hypertension, 2020, 22, 1835-1845.	1.0	7
49	Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial. Clinical Therapeutics, 2020, 42, 2021-2035.e3.	1.1	6
50	Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: Findings from the EPICOR Asia study. International Journal of Cardiology, 2020, 315, 1-8.	0.8	6
51	Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry. Journal of Interventional Cardiology, 2020, 2020, 1-9.	0.5	7
52	Efficacy and Safety of Long-Term and Short-Term Dual Antiplatelet Therapy: A Meta-Analysis of Comparison between Asians and Non-Asians. Journal of Clinical Medicine, 2020, 9, 652.	1.0	10
53	Prognostic Effects of Treatment Strategies for Left Main Versus Non-Left Main Bifurcation Percutaneous Coronary Intervention With Current-Generation Drug-Eluting Stent. Circulation: Cardiovascular Interventions, 2020, 13, e008543.	1.4	30
54	Complete Revascularization of Multivessel Coronary Artery Disease Does Not Improve Clinical Outcome in ST-Segment Elevation Myocardial Infarction Patients with Reduced Left Ventricular Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 232.	1.0	7

#	Article	IF	Citations
55	Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease. Circulation, 2020, 141, 1437-1446.	1.6	136
56	SYNTAX Score and SYNTAX Score II Can Predict the Clinical Outcomes of Patients with Left Main and/or 3-Vessel Disease Undergoing Percutaneous Coronary Intervention in the Contemporary Cobalt-Chromium Everolimus-Eluting Stent Era. Korean Circulation Journal, 2020, 50, 22.	0.7	8
57	2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction. Korean Circulation Journal, 2020, 50, 845.	0.7	16
58	Ethnic Differences in Oral Antithrombotic Therapy. Korean Circulation Journal, 2020, 50, 645.	0.7	13
59	Association of Side-Branch Treatment and Patient Factors in Left Anterior Descending Artery True Bifurcation Lesions: Analysis from the GRAND-DES Pooled Registry. Journal of Interventional Cardiology, 2020, 2020, 1-9.	0.5	1
60	One-Year Clinical Outcomes between Single- versus Multi-Staged PCI for ST Elevation Myocardial Infarction with Multi-Vessel Coronary Artery Disease: from Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH). Korean Circulation Journal, 2020, 50, 220.	0.7	5
61	Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 120-129.	1.0	14
62	Toll-like receptor mediated inflammation requires FASN-dependent MYD88 palmitoylation. Nature Chemical Biology, 2019, 15, 907-916.	3.9	87
63	The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era. Journal of Interventional Cardiology, 2019, 2019, 1-13.	0.5	12
64	Prognosis and Predictors of Mortality in Patients Suffering Myocardial Infarction With Nonâ€Obstructive Coronary Arteries. Journal of the American Heart Association, 2019, 8, e011990.	1.6	96
65	Comparison of Two-Year Outcomes of Acute Myocardial Infarction Caused by Coronary Artery Spasm Versus that Caused by Coronary Atherosclerosis. American Journal of Cardiology, 2019, 124, 1493-1500.	0.7	5
66	Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. Clinical Therapeutics, 2019, 41, 233-248.e9.	1.1	11
67	Identification of Latrophilin-2 as a Novel Cell-Surface Marker for the Cardiomyogenic Lineage and Its Functional Significance in Heart Development. Circulation, 2019, 139, 2910-2912.	1.6	10
68	Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stentã€€â€• 3-Year Outcomes From the HOSTâ€“ASSURE Randomized Clinical Trial â€•. Circulation Journal, 2019, 83, 1489-1497.	0.7	2
69	Sildenafil Reduces Neointimal Hyperplasia after Angioplasty and Inhibits Platelet Aggregation via Activation of cGMP-dependent Protein Kinase. Scientific Reports, 2019, 9, 7769.	1.6	25
70	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	1.0	335
71	Development and Validation of an Ischemic and Bleeding Risk Evaluation Tool in East Asian Patients Receiving Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 2019, 119, 1182-1193.	1.8	16
72	Prognostic Implications of Doorâ€toâ€Balloon Time and Onsetâ€toâ€Door Time on Mortality in Patients With STâ€Segmentâ€“Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Journal of the American Heart Association, 2019, 8, e012188.	1.6	115

#	Article	IF	Citations
73	Comparison of Longâ€Term Clinical Outcome Between Multivessel Percutaneous Coronary Intervention Versus Infarctâ€Related Arteryâ€“Only Revascularization for Patients With STâ€Segmentâ€“Elevation Myocardial Infarction With Cardiogenic Shock. Journal of the American Heart Association, 2019, 8, e013870.	1.6	18
74	2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Science Bulletin, 2019, 64, 166-179.	4.3	34
75	Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. Thrombosis and Haemostasis, 2019, 119, 149-162.	1.8	107
76	Radial Versus Femoral Access With or Without Vascular Closure Device in Patients With Acute Myocardial Infarction. American Journal of Cardiology, 2019, 123, 742-749.	0.7	9
77	Prognostic Impact of Î²-Blocker Dose After Acute Myocardial Infarction. Circulation Journal, 2019, 83, 410-417.	0.7	32
78	The Proximal Optimization Technique Improves Clinical Outcomes When Treated without Kissing Ballooning in Patients with a Bifurcation Lesion. Korean Circulation Journal, 2019, 49, 485.	0.7	12
79	Identification of Adult Mesodermal Progenitor Cells and Hierarchy in Atherosclerotic Vascular Calcification. Stem Cells, 2018, 36, 1075-1096.	1.4	7
80	Optimal Timing of Percutaneous Coronary Intervention in Patients With Nonâ€“ST-Segment Elevation Myocardial Infarction Complicated by Acute Decompensated Heart Failure (from the Korea Acute) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Cardiology, 2018, 121, 1285-1292.	0.7	6
81	Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study. Clinical Therapeutics, 2018, 40, 676-691.e1.	1.1	21
82	Comparison of the planned oneâ€•and elective twoâ€•stent techniques in patients with coronary bifurcation lesions with or without acute coronary syndrome from the COBIS II Registry. Catheterization and Cardiovascular Interventions, 2018, 92, 1050-1060.	0.7	5
83	Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction With Cardiogenic Shock. Journal of the American College of Cardiology, 2018, 71, 844-856.	1.2	77
84	Hepatocyte Growth Factor Improves the Therapeutic Efficacy of Human Bone Marrow Mesenchymal Stem Cells via RAD51. Molecular Therapy, 2018, 26, 845-859.	3.7	27
85	Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study. Clinical Therapeutics, 2018, 40, 50-63.e3.	1.1	9
86	A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe) Tj ETQq0 0 0 rgBT /Overlock 10	1.1	37
87	Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study. Thrombosis and Haemostasis, 2018, 118, 591-600.	1.8	50
88	Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization. Journal of Cardiology, 2018, 71, 36-43.	0.8	28
89	Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial. Clinical Therapeutics, 2018, 40, 83-94.	1.1	23
90	Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome. PLoS ONE, 2018, 13, e0207386.	1.1	14

#	Article	IF	Citations
91	Dual Antiplatelet Therapy Duration Determines Outcome After 2- But Not 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 2453-2463.	1.1	33
92	10-Year Outcomes of Stents Versus Coronary Artery Bypass Grafting for LeftÂMainÂCoronaryÂArtery Disease. Journal of the American College of Cardiology, 2018, 72, 2813-2822.	1.2	69
93	The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and â€œAsian Paradoxâ€• Korean Circulation Journal, 2018, 48, 537.	0.7	52
94	Impact of Optimized Procedure-Related Factors in Drug-Eluting Balloon Angioplasty for Treatment of In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 969-978.	1.1	30
95	Farewell to Drug-Eluting Balloons for In-Stent Restonsis?. JACC: Cardiovascular Interventions, 2018, 11, 992-994.	1.1	2
96	The natural course of nonculprit coronary artery lesions; analysis by serial quantitative coronary angiography. BMC Cardiovascular Disorders, 2018, 18, 130.	0.7	5
97	Imprinted gene Zinc finger protein 127 is a novel regulator of master pluripotency transcription factor, Oct4. BMB Reports, 2018, 51, 242-248.	1.1	4
98	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet, The, 2017, 389, 1025-1034.	6.3	840
99	Treatment for in-stent restenosis using drug-eluting balloon: Importance of procedural optimization rather than device itself. International Journal of Cardiology, 2017, 242, 5.	0.8	1
100	Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry. International Journal of Cardiology, 2017, 230, 181-190.	0.8	22
101	A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial. American Heart Journal, 2017, 185, 17-25.	1.2	16
102	Benefit of Vasodilating Î²â€Blockers in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention: Nationwide Multicenter Cohort Study. Journal of the American Heart Association, 2017, 6, .	1.6	10
103	Predictors of candesartan's effect on vascular reactivity in patients with coronary artery disease. Cardiovascular Therapeutics, 2017, 35, e12291.	1.1	4
104	Treatment for in-stent restenosis: patient-specific decision rather than universal recommendation. Journal of Thoracic Disease, 2016, 8, E847-E849.	0.6	3
105	Clinical Outcomes in Patients with Deferred Coronary Lesions according to Disease Severity Assessed by Fractional Flow Reserve. Journal of Korean Medical Science, 2016, 31, 1929.	1.1	2
106	Multicenter Cohort Study of Acute Myocardial Infarction in Koreaã€€â€“ Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry â€“. Circulation Journal, 2016, 80, 1427-1436.	0.7	166
107	Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registryâ€”National Institute of Health. International Journal of Cardiology, 2016, 215, 193-200.	0.8	70
108	Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. Journal of the American College of Cardiology, 2016, 68, 1851-1864.	1.2	319

#	Article	IF	Citations
109	Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era. JACC: Cardiovascular Interventions, 2016, 9, 2097-2109.	1.1	61
110	Usefulness of the Baseline Syntax Score to Predict 3-Year Outcome After Complete Revascularization by Percutaneous Coronary Intervention. American Journal of Cardiology, 2016, 118, 641-646.	0.7	15
111	Effect of fixedâ€dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRSâ€ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovascular Therapeutics, 2016, 34, 371-382.	1.1	45
112	Major Predictors of Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Coronary Bifurcation Lesions With 2-Stent Strategy. JACC: Cardiovascular Interventions, 2016, 9, 1879-1886.	1.1	25
113	Activation of Protein Kinase G (PKG) Reduces Neointimal Hyperplasia, Inhibits Platelet Aggregation, and Facilitates Re-endothelialization. Scientific Reports, 2016, 6, 36979.	1.6	11
114	Impact of smoking status on clinical outcomes after successful chronic total occlusion intervention: Korean national registry of CTO intervention. Catheterization and Cardiovascular Interventions, 2016, 87, 1050-1062.	0.7	6
115	Effects of celecoxib on vascular changes after coronary intervention: A serial volumetric intravascular ultrasound analysis from the mini-COREA randomized clinical trial. International Journal of Cardiology, 2016, 202, 240-243.	0.8	0
116	CD82/KAI1 Maintains the Dormancy of Long-Term Hematopoietic Stem Cells through Interaction with DARC-Expressing Macrophages. Cell Stem Cell, 2016, 18, 508-521.	5.2	130
117	Harmonizing Optimal Strategy for Treatment of coronary artery diseases â€“ comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial. Trials, 2015, 16, 409.	0.7	12
118	Role of Zscan4 in secondary murine iPSC derivation mediated by protein extracts of ESC or iPSC. Biomaterials, 2015, 59, 102-115.	5.7	6
119	The efficacy and safety of mechanical hemodynamic support in patients undergoing high-risk percutaneous coronary intervention with or without cardiogenic shock: Bayesian approach network meta-analysis of 13 randomized controlled trials. International Journal of Cardiology, 2015, 184, 36-46.	0.8	25
120	Comparison Among Drug-Eluting Balloon, Drug-Eluting Stent, and PlainÂBalloon Angioplasty for the Treatment of In-Stent Restenosis. JACC: Cardiovascular Interventions, 2015, 8, 382-394.	1.1	97
121	Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions. JACC: Cardiovascular Interventions, 2015, 8, 1318-1331.	1.1	36
122	Long-Term Patient-Related and Lesion-Related Outcomes After Real-World Fractional Flow Reserve Use. Journal of Invasive Cardiology, 2015, 27, 410-5.	0.4	6
123	A Randomized Comparison of Platinum Chromium-Based Everolimus-Eluting Stents Versus Cobalt Chromium-Based Zotarolimus-Eluting Stents in All-Comers Receiving Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 63, 2805-2816.	1.2	80
124	Differential Prognostic Impact of Treatment Strategy Among Patients With Left Main Versus Nonâ€Left Main Bifurcation Lesions Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 255-263.	1.1	64
125	Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. European Heart Journal, 2014, 35, 1147-1158.	1.0	152
126	Adenylyl Cyclase-Associated Protein 1 Is a Receptor for Human Resistin and Mediates Inflammatory Actions of Human Monocytes. Cell Metabolism, 2014, 19, 484-497.	7.2	213

#	Article	IF	Citations
127	Three-Year Patient-Related and Stent-Related Outcomes of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice (from the) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 2014, 114, 1329-1338.	0.7	20
128	The impact of residual coronary lesions on clinical outcomes after percutaneous coronary intervention: Residual SYNTAX score after percutaneous coronary intervention in patients from the Efficacy of Xience/Promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) registry. American Heart Journal, 2014, 167, 384-392.e5.	1.2	34
129	Everolimus-Eluting Xience V/Promus Versus Zotarolimus-Eluting Resolute Stents in Patients With Diabetes Mellitus. JACC: Cardiovascular Interventions, 2014, 7, 471-481.	1.1	59
130	Comparative Study of Efficacy of Dopaminergic Neuron Differentiation between Embryonic Stem Cell and Protein-Based Induced Pluripotent Stem Cell. PLoS ONE, 2014, 9, e85736.	1.1	14
131	Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice. Journal of the American College of Cardiology, 2013, 61, 536-544.	1.2	50
132	Adjunctive Cilostazol Versus Double-Dose Clopidogrel After Drug-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2013, 6, 932-942.	1.1	32
133	Predictors and Outcomes of Side Branch Occlusion After Main Vessel Stenting in Coronary Bifurcation Lesions. Journal of the American College of Cardiology, 2013, 62, 1654-1659.	1.2	188
134	Phenotypic modulation of human cardiospheres between stemness and paracrine activity, and implications for combined transplantation in cardiovascular regeneration. Biomaterials, 2013, 34, 9819-9829.	5.7	12
135	Vascular progenitor cells with decalcifying potential: a step toward prevention or treatment of atherosclerotic vascular calcification?. Expert Review of Cardiovascular Therapy, 2013, 11, 937-939.	0.6	1
136	Generation of human secondary cardiospheres as a potent cell processing strategy for cell-based cardiac repair. Biomaterials, 2013, 34, 651-661.	5.7	20
137	Highly angiogenic CXCR4+CD31+ monocyte subset derived from 3D culture of human peripheral blood. Biomaterials, 2013, 34, 1929-1941.	5.7	24
138	Vascular Calcifying Progenitor Cells Possess Bidirectional Differentiation Potentials. PLoS Biology, 2013, 11, e1001534.	2.6	34
139	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ, The, 2013, 347, f6530-f6530.	3.0	194
140	Usefulness of the SYNTAX and Clinical SYNTAX Scores in Predicting Clinical Outcome After Unrestricted Use of Sirolimus- and Everolimus-Eluting Stents. Circulation Journal, 2013, 77, 2912-2921.	0.7	19
141	Comparison of Hyperemic Efficacy Between Central and Peripheral Venous Adenosine Infusion for Fractional Flow Reserve Measurement. Circulation: Cardiovascular Interventions, 2012, 5, 401-405.	1.4	59
142	Final kissing ballooning and long-term clinical outcomes in coronary bifurcation lesions treated with 1-stent technique: results from the COBIS registry. Heart, 2012, 98, 225-231.	1.2	101
143	Impact of Coronary Bifurcation Angle on Clinical Outcomes after Percutaneous Coronary Intervention in Real-World Practice: Results from the COBIS Registry. Cardiology, 2012, 122, 216-224.	0.6	15
144	Secondary Sphere Formation Enhances the Functionality of Cardiac Progenitor Cells. Molecular Therapy, 2012, 20, 1750-1766.	3.7	34

#	Article	IF	Citations
145	Options to Overcome Clopidogrel Response Variability. Circulation Journal, 2012, 76, 287-292.	0.7	27
146	Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet, The, 2012, 379, 1393-1402.	6.3	854
147	Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents. Circulation, 2012, 125, 505-513.	1.6	555
148	Clinical Predictors of High Posttreatment Platelet Reactivity to Clopidogrel in Koreans. Cardiovascular Therapeutics, 2012, 30, 5-11.	1.1	54
149	Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart, 2012, 98, 1366-1372.	1.2	34
150	Regeneration of peripheral nerves by transplanted sphere of human mesenchymal stem cells derived from embryonic stem cells. Biomaterials, 2012, 33, 7039-7046.	5.7	43
151	The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial. Trials, 2012, 13, 29.	0.7	8
152	Relationship Between Fractional Flow Reserve and Angiographic and Intravascular Ultrasound Parameters in Ostial Lesions. JACC: Cardiovascular Interventions, 2012, 5, 409-415.	1.1	48
153	Spherical Bullet Formation via E-cadherin Promotes Therapeutic Potency of Mesenchymal Stem Cells Derived From Human Umbilical Cord Blood for Myocardial Infarction. Molecular Therapy, 2012, 20, 1424-1433.	3.7	126
154	Analysis of Differential Proteomes of Induced Pluripotent Stem Cells by Protein-Based Reprogramming of Fibroblasts. Journal of Proteome Research, 2011, 10, 977-989.	1.8	18
155	Adipokine Resistin Is a Key Player to Modulate Monocytes, Endothelial Cells, and Smooth Muscle Cells, Leading to Progression of Atherosclerosis in Rabbit Carotid Artery. Journal of the American College of Cardiology, 2011, 57, 99-109.	1.2	102
156	Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart Disease. Journal of the American College of Cardiology, 2011, 57, 280-289.	1.2	177
157	Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, 1945-1954.	1.2	383
158	Everolimus-Eluting Versus Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, 1844-1854.	1.2	137
159	Clinical Outcomes of High On-Treatment Platelet Reactivity in Koreans Receiving Elective Percutaneous Coronary Intervention (from Results of the CROSS VERIFY Study). American Journal of Cardiology, 2011, 108, 1556-1563.	0.7	39
160	Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood, 2010, 116, 386-395.	0.6	217
161	Real World' Comparison of Drug-Eluting Stents vs Bare Metal Stents in the Treatment of Unselected Patients With Acute ST-Segment Elevation Myocardial Infarction. Circulation Journal, 2010, 74, 1111-1120.	0.7	20
162	Novel Embryoid Bodyâ€"Based Method to Derive Mesenchymal Stem Cells from Human Embryonic Stem Cells. Tissue Engineering - Part A, 2010, 16, 705-715.	1.6	63

#	Article	IF	Citations
163	Identification of the KAI1 metastasis suppressor gene as a hypoxia target gene. Biochemical and Biophysical Research Communications, 2010, 393, 179-184.	1.0	18
164	Does â€œlate catch-upâ€•exist in drug-eluting stents: Insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents. American Heart Journal, 2010, 159, 446-453.e3.	1.2	52
165	Impact of Myocardial Infarct Proteins and Oscillating Pressure on the Differentiation of Mesenchymal Stem Cells: Effect of Acute Myocardial Infarction on Stem Cell Differentiation. Stem Cells, 2008, 26, 1901-1912.	1.4	60
166	Impact of Intracoronary Cell Therapy on Left Ventricular Function in the Setting of Acute Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, 1761-1767.	1.2	484
167	Synergistic Neovascularization by Mixed Transplantation of Early Endothelial Progenitor Cells and Late Outgrowth Endothelial Cells. Circulation, 2005, 112, 1618-1627.	1.6	567
168	Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet, The, 2004, 363, 751-756.	6.3	871